A Phase Ib/II Study of the Safety, Tolerability, and Efficacy of a Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic Cancer

This study aims to evaluate the safety, tolerability, and efficacy of HRS-2329 in combination with other anti-tumor therapies in participants with advanced pancreatic cancer harboring RAS mutations or amplifications.

开始日期2026-08-15

申办/合作机构

浙江大学

ChiCTR2600128718

/ Not yet recruiting临床2期IIT

A Prospective, Single-Arm, Phase II Clinical Study of Nimotuzumab Combined with Neoadjuvant Chemotherapy in the Treatment of Locally Advanced Resectable Oral Squamous Cell Carcinoma

开始日期2026-08-01

申办/合作机构

浙江大学医学院附属第一医院（浙江省第一医院）

NCT07706985

/ Recruiting临床3期IIT

Efficacy and Safety of TPC Induction Chemotherapy Combined With Nimotuzumab and Toripalimab "Immune Sandwich" Regimen Versus Full-Course Immunotherapy for Locally Advanced Nasopharyngeal Carcinoma: A Multicenter, Randomized, Open-Label, Non-Inferiority Phase III Clinical Study

Immunotherapy combined with chemoradiotherapy has become standard care for locally advanced nasopharyngeal carcinoma, yet radiotherapy-induced lymphopenia may impair the efficacy of concurrent PD-1 blockade. Existing evidence supports synergistic anti-tumor activity between the anti-EGFR antibody nimotuzumab and toripalimab. This multicenter, open-label, non-inferiority Phase III trial randomizes eligible stage III-IVA LA-NPC patients 1:1 to two arms. The experimental group receives an "immune sandwich" regimen: TPC induction plus nimotuzumab and toripalimab, concurrent radiotherapy with weekly nimotuzumab only, followed by toripalimab maintenance. The control arm adopts full-course toripalimab throughout induction, concurrent radiotherapy and adjuvant phases. The primary endpoint is 3-year event-free survival, with secondary endpoints covering overall survival, local/distant control rates, objective response rate and treatment-related toxicities. A total of 566 subjects will be enrolled to verify whether the simplified sandwich strategy delivers non-inferior survival with better safety profiles.

开始日期2026-07-20

申办/合作机构

中山大学

[+1]

100 项与尼妥珠单抗相关的临床结果

登录后查看更多信息

100 项与尼妥珠单抗相关的转化医学

登录后查看更多信息

100 项与尼妥珠单抗相关的专利（医药）

登录后查看更多信息

406

项与尼妥珠单抗相关的文献（医药）

2026-08-01·INSECT MOLECULAR BIOLOGY

Identification and functional characterization of key ecdysteroid biosynthesis and signalling genes regulating moulting and metamorphosis in Dastarcus helophoroides

Article

作者: Shaheen, Tayyab ; Tang, Guanghui ; Wu, Zhaochen ; Zhang, Zhengqing ; Sun, Yan ; Guo, Jiali ; Zhang, Mengxue

Abstract:

Dastarcus helophoroides is an important ectoparasitoid used in the biological control of longhorn beetles. Its first‐instar larvae actively seek hosts and progress through four larval instars before pupation. Throughout these developmental stages, 20‐hydroxyecdysone (20E) plays a pivotal role in initiating and regulating moulting and metamorphosis; however, the specific genes and underlying molecular mechanisms in D. helophoroides remain uncharacterized. In this study, comparative transcriptome analysis across larval development identified differentially expressed genes (DEGs) associated with cuticle remodelling, hormone metabolism and stage‐specific metabolic and cellular reprogramming. RT‐qPCR validation revealed stage‐specific expression patterns of 20E biosynthesis and signalling pathway genes, with EcR , Br‐C , E93 and HR39 peaking during the larval–prepupal transition, whereas CYP18A1 , E74A , E75B , HR3 and FTZ‐F1 were highly expressed in early instars. RNAi targeting the eight key genes ( CYP315A1 , CYP314A1 , EcR , USP , Br‐C , E93 , HR39 and FTZ‐F1 ) severely disrupted metamorphosis and reduced adult eclosion by 47.83–100%. The developmental arrests were accompanied by stage‐specific morphological abnormalities, including abnormal pigmentation, wing deformities and malformed prepupae and pupae. This study identifies key ecdysteroid biosynthesis and signalling genes as critical regulators of D. helophoroides development, providing insights into growth regulation and artificial rearing optimization in this parasitoid biocontrol agent.

2026-07-01·MedComm

EGFR‐Targeting IgG1 Antibody Enhances NK Cell‐Mediated Tumor Killing in KRAS‐Mutant Pancreatic Cancer

Article

作者: Li, Xiaoxiao ; Li, Ping ; Ren, Minghan ; Wang, Junjin ; Liu, Zimin ; Ren, He ; Xiao, Ruoxi ; Lei, Ke ; Gong, Ruining ; Zhao, Chenyang ; Sun, Xiaoyuan

ABSTRACT:

KRAS‐mutant pancreatic ductal adenocarcinoma (PDAC) exhibits intrinsic resistance to epidermal growth factor receptor (EGFR)‐targeted therapies owing to constitutive downstream pathway activation. Nevertheless, IgG1 antibodies may retain therapeutic activity through natural killer (NK) cell‐mediated antibody‐dependent cellular cytotoxicity (ADCC), thereby bypassing EGFR downstream signaling. However, whether EGFR‐targeted IgG1 antibody‐mediated ADCC remains effective in KRAS‐mutant PDAC, and what determines therapeutic responsiveness, remain unclear. Here, we investigated whether nimotuzumab‐mediated ADCC remains effective despite oncogenic KRAS signaling and explored the determinants of its therapeutic efficacy. Using complementary in vitro and in vivo models, including PDAC cell–NK cell co‐culture systems, 3D tumor spheroids, and immunodeficient mouse models (subcutaneous and circulating tumor cell‐derived xenografts), we demonstrated that combined nimotuzumab and adoptive NK cell therapy exerts potent antitumor efficacy in PDAC. Mechanistically, this treatment drives robust NK cell functional activation (CD107a/IFN‐γ/TNF‐α), enhances tumor homing, and induces immunogenic cell death. Collectively, our findings demonstrate that KRAS mutations do not compromise nimotuzumab‐mediated ADCC, whereas tumor EGFR expression serves as a predictor of therapeutic responsiveness. Ultimately, this study establishes EGFR‐directed NK cell immunotherapy as a promising therapeutic strategy for KRAS‐mutant PDAC and provides a rationale for integrating targeted antibodies with cellular immunotherapies in other EGFR‐expressing malignancies.

2026-06-06·ONCOLOGIST

Pancreatic ductal adenocarcinoma with ITSN1-ALK fusion: sustained response to alectinib with 19-month progression-free survival

Article

作者: Liu, Chaoxing ; Chen, Lixuan ; Wang, Xiaoyan

Abstract:

Background:

Pancreatic ductal adenocarcinoma (PDAC) harboring ALK fusions is exceptionally rare, with limited data on clinical outcomes with ALK inhibitor therapy.

Case summary:

A 70-year-old man presented with stage IV PDAC (pancreatic tail primary with liver and lymph node metastases). Following progression on first-line gemcitabine/nab-paclitaxel, tumor next-generation sequencing identified an ITSN1-ALK fusion (62.12% abundance) and TP53 mutation. The patient received alectinib 600 mg twice daily beginning at Month 4. Tumor markers declined markedly (CA19-9 from 234 to 12.7 U/mL by Month 7), and radiographic stability was maintained through Month 22. Upon progression at Month 23, treatment was switched to lorlatinib followed by capecitabine plus nimotuzumab. The patient remains alive at last follow-up (Month 29). Progression-free survival on alectinib was 19 months—substantially exceeding the median of 5.0 months reported for ALK fusion-positive gastrointestinal cancers.

Conclusion:

This first report of ITSN1-ALK fusion in PDAC demonstrates that ALK inhibition can produce durable, clinically meaningful benefit. This case reinforces the importance of comprehensive genomic profiling in KRAS-wildtype PDAC to identify actionable rare fusions.

Implications for practice:

Oncologists should consider broad next-generation sequencing, including fusion detection, for patients with KRAS-wildtype PDAC. When an ALK fusion is identified, ALK inhibitor therapy can yield durable disease control.

123

项与尼妥珠单抗相关的新闻（医药）

2026-07-25

·研日新

研日新周报 ·3| 07月26日全科医学 | 血液内科 | 皮肤科

周报精选医学文献近7天周度精选20篇，覆盖重点学科进展本文支持继续浏览摘要内容；完整摘要、收藏文章、订阅管理等完整功能，请前往小程序「医研日新」。前往小程序查看更多与订阅收藏 1. Evaluation of CD68+ macrophages in relation to kidney outcomes in immunoglobulin light-chain amyloidosis. [Immunoglobulin Light-chain Amyloidosis] Kidney international | 2026-07-24 | IF 89.6 AI在评估AL淀粉样变性患者肾脏预后时，应同时关注肾活检中CD68⁺巨噬细胞浸润程度和化疗后淀粉样蛋白消退情况，两者可协同预测患者进展至肾脏替代治疗的风险。摘要The clinical course of systemic amyloidosis reflects the equilibrium between amyloid deposition and clearance, which varies across disease contexts. The mechanisms underlying amyloid clearance in vivo remain unclear, though experimental data implicate macrophage-mediated phagocytosis. Here we evaluated the impact of CD68+ macrophage infiltration in diagnostic kidney biopsies on kidney o...查看完整摘要 2. Distinct brain regions mediate regulation of food intake in response to GIPR agonism or antagonism. [Obesity] Nature metabolism | 2026-07-24 | IF 18.9 AI该研究揭示了GIPR在不同脑区介导减重的差异性机制，提示联合靶向GIPR激动与拮抗的双重策略可能通过互补神经通路实现更优减重效果，为代谢性疾病个体化治疗提供新思路。摘要The development of dual agonists for the glucagon-like peptide-1 receptor (GLP-1R) and glucose-dependent insulinotropic polypeptide receptor (GIPR) has been a landmark moment in the treatment of type 2 diabetes and obesity. However, for reasons that are incompletely understood, in preclinical and clinical studies, adding either a GIPR agonist or GIPR antagonist to GLP-1R agonism causes additional ...查看完整摘要 3. JN.1-adapted vaccination is associated with readjustment of ancestral memory B cells toward neutralization within the JN.1 antigenic space. [COVID-19] Nature communications | 2026-07-24 | IF 14.7 AIJN.1适配加强疫苗通过精细化预先存在的记忆B细胞，而非大量招募新B细胞，有效增强对当前流行变异株的中和保护。摘要The antigenic drift of SARS-CoV-2 toward the JN.1 lineage has prompted the development of variant-adapted COVID-19 booster vaccines. However, these boosters are thought to primarily recall pre-existing memory B cells (MBC), raising concerns about their ability to realign the immune response in highly pre-exposed populations. Here we analyze antibody and B cell responses in pre-exposed individuals ...查看完整摘要 4. COVID-19 vaccination timing, relative to acute COVID-19, and subsequent risk of long COVID. [COVID-19] EBioMedicine | 2026-07-24 | IF 9.7 AICOVID-19疫苗接种可降低16%的长新冠发病风险，且该保护效力在接种后7个月内保持稳定，建议临床积极推动疫苗接种以预防长新冠。摘要Vaccination is a vital tool in preventing acute COVID-19 and may confer additional protection against Long COVID, although it is unclear whether this protection wanes over time. We assessed electronic health record (EHR) data from a national, retrospective cohort of patients, comparing the 12-month cumulative incidence of Long COVID (ICD-10 code U09.9) among (A) patients who were vaccinated versus...查看完整摘要 5. Oleoylethanolamide attenuates early skeletal muscle metabolic remodeling induced by short-term high-fat diet exposure. [Obesity] Pharmacological research | 2026-07-24 | IF 9.1 AI即使在肥胖明确诊断前，高脂饮食已悄然损害骨骼肌代谢功能；早期干预（如OEA）可能延缓肥胖相关代谢并发症的进展。摘要Obesity develops through progressive metabolic alterations that arise long before overt disease, highlighting the need for pharmacological strategies capable of targeting the earliest tissue adaptations to fat nutrient excess. Skeletal muscle plays a central role in systemic metabolic homeostasis and is among the first organs affected by high-fat diet (HFD) exposure. Oleoylethanolamide (OEA), a pe...查看完整摘要 6. Izalontamab Brengitecan (Iza-Bren), a First-in-Class EGFR-HER3 Bispecific Antibody-Drug Conjugate in Extensive-Stage Small Cell Lung Cancer: Results From a Phase Ib Study. [Thrombocytopenia] Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2026-07-24 | IF 42.1 AIIza-bren在复发ES-SCLC二线治疗中展现高缓解率（72.7%）和可控安全性，为该类患者提供了新的有效治疗选择。摘要Small cell lung cancer (SCLC) remains one of the most aggressive malignancies, with limited treatment options beyond frontline chemo-immunotherapy. Izalontamab brengitecan (iza-bren, BL-B01D1) is a first-in-class bispecific antibody-drug conjugate cotargeting epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 3 (HER3). We expanded the SCLC cohort to further evaluate...查看完整摘要 7. Genomic correlates of clinical CAR T cell activity. [Lymphoma] Science immunology | 2026-07-24 | IF 17.6 AI生殖系基因变异是CAR T细胞治疗毒性和疗效的重要预测因子，PTPN22、ADAMTSL3等基因检测有望指导个体化治疗决策。摘要Germline variants influence immune checkpoint inhibitor responses, but their role in engineered immune cell therapies, such as chimeric antigen receptor T cells (CAR T cells), remains unclear. We integrated whole germline sequencing from patients with lymphoma treated with axicabtagene ciloleucel CAR T cell products in the ZUMA-1 and ZUMA-7 clinical trials with detailed biomarker and functional an...查看完整摘要 8. Assessing the reproductive lifespan of female cancer survivors using AMH: a meta-synthesis of longitudinal studies. [Lymphoma] Human reproduction update | 2026-07-24 | IF 14.8 AIAMH可作为评估癌症治疗性腺毒性及预测女性幸存者卵巢储备恢复的有效生物标志物，保留卵巢功能的幸存者生殖衰老轨迹与健康人群相当，为生育力保存咨询提供重要依据。摘要Anti-Müllerian hormone (AMH) is widely used to assess gonadotoxicity related to anti-cancer treatments and to measure ovarian function in cancer survivors. The extent of AMH decline across malignancies and treatment regimens and the degree of subsequent recovery have not been systematically quantified. The primary objective of this review was to quantify the change in AMH following cancer treatmen...查看完整摘要 9. Induction toripalimab plus chemotherapy sequential concurrent chemoradiotherapy with nimotuzumab followed by toripalimab maintenance in stage IVB hypopharyngeal squamous cell carcinoma: a single-arm phase 2 study. [Mucositis] Clinical Trial, Phase II | Journal for immunotherapy of cancer | 2026-07-24 | IF 10.3 AI替雷利珠单抗联合化疗诱导+同步放化疗（尼妥珠单抗）+免疫维持的四阶段治疗模式在IVB期下咽鳞状细胞癌中展现出高缓解率、显著喉保留率及可控毒性，外周血T细胞亚群有望成为预测疗效的生物标志物。摘要Optimal induction chemoimmunotherapy sequential concurrent chemoradiotherapy (cCRT) in locally advanced hypopharyngeal squamous cell carcinoma (HSCC) remains undefined. This study aimed to evaluate toripalimab plus chemotherapy sequential cCRT with nimotuzumab, followed by toripalimab maintenance in unresectable stage IVB HSCC. In this single-arm, open-label, phase 2 study, untreated patients rece...查看完整摘要 10. Clinical utility of real-time comprehensive molecular testing in large B-cell lymphoma. [Lymphoma] Blood advances | 2026-07-24 | IF 7.4 AI综合WES+RNA-seq检测可在约8天内完成LBCL分子分型，为临床提供可行的分子风险评估工具，尤其EFS24高危患者可通过暗区签名和微环境分类识别。摘要Due to the rapidly evolving landscape of targeted therapies, there is an unmet need for comprehensive molecular profiling to guide treatment decisions for patients with large B-cell lymphoma (LBCL). Therefore, we designed a pilot study to assess the feasibility and turnaround time (TAT) of a comprehensive whole exome sequencing (WES) and transcriptome sequencing (RNA-seq) assay in patients with LB...查看完整摘要 11. Expanding the Therapeutic Horizon for Chronic Spontaneous Urticaria - Finally. [Urticaria] 社论 | Journal of the American Academy of Dermatology | 2026-07-24 | IF 12.8 AICSU已进入生物制剂精准治疗时代，抗IgE靶向药物为难治性患者提供了安全有效的治疗选择。 12. The melanocytic transcriptomic state is independently associated with poor overall survival in patients with metastatic melanoma. [Melanoma] Science advances | 2026-07-24 | IF 11.7 AI黑色素细胞转录状态可作为转移性黑色素瘤预后分层和指导个体化治疗决策的独立生物标志物。摘要Melanomas display distinct transcriptomic states, but it remains unclear how they associate with clinical outcomes. We performed digital spatial RNA profiling (DSP-RNA) of metastatic tumors from patients to investigate how transcriptomic states correlate with melanoma specific survival (MSS) and acral melanoma (AM). We performed DSP-RNA across a tissue microarray constructed from 111 patients with...查看完整摘要 13. Autocrine CysLT1R-ERK/YAP signaling drives melanoma progression and reveals a targetable oncogenic GPCR axis. [Melanoma] Oncogene | 2026-07-24 | IF 6.9 AICysLT₁R作为GPCR靶点有望克服现有黑色素瘤治疗耐药困境，MK571等抑制剂或可开发为新型抗黑色素瘤药物。摘要Cutaneous melanoma remains the most lethal skin cancer due to profound tumor heterogeneity and the frequent development of resistance to current therapies. Here, we identify the cysteinyl leukotriene receptor 1 (CysLT1R) as a previously unrecognized driver of melanoma progression. Analysis of bulk RNA-sequencing datasets from The Cancer Genome Atlas (TCGA) revealed significantly elevate...查看完整摘要 14. Disease context dictates the cellular targets of IL-17 in inflammatory skin disease. [Psoriasis] The Journal of investigative dermatology | 2026-07-24 | IF 5.7 AI化脓性汗腺炎与银屑病的IL-17致病机制存在细胞靶点差异，前者主要依赖成纤维细胞，后者需同时阻断角质形成细胞和成纤维细胞的IL-17信号，提示精准治疗需考虑疾病特异性细胞通路。摘要IL-17 and TNF blockade effectively treats hidradenitis suppurativa and psoriasis, yet the relative importance of the different cell types that respond to IL-17 and TNF remains unresolved. Keratinocytes are viewed as the dominant effector cells, whereas fibroblasts have recently emerged as important contributors. In mice, topical imiquimod induces IL-17- and TNF-dependent skin inflammation and mode...查看完整摘要 15. Contagious fish cancer overruns New England lake. [Melanoma] News | Science (New York, N.Y.) | 2026-07-23 | IF 44.7 AI传染性肿瘤虽在人类中罕见，但该研究提示需关注免疫抑制状态下肿瘤细胞异体传播的可能性，对器官移植及免疫缺陷患者的肿瘤筛查具有警示意义。摘要Genetic studies reveal rare example of identical transmissible tumors. 16. AI-based clinician decision support system for diagnosis of inherited retinal diseases: a multicenter, randomized trial. [Eye Diseases] Nature medicine | 2026-07-24 | IF 58.7 AIRetina4IRD作为AI辅助工具可显著提升遗传性视网膜疾病的基因型预测准确率，在基因检测前为临床医生提供可靠的决策支持，有望改善诊疗效率。摘要The accurate and timely diagnosis of inherited retinal diseases (IRDs) represents an unmet clinical need in ophthalmology, as the current pathways rely on resource-intensive phenotyping, multidisciplinary expertise and genetic testing. Here we developed Retina4IRD, an artificial intelligence (AI)-based clinician decision support system (CDSS) that predicts 17 genotype categories from retina images...查看完整摘要 17. Bridging complexity and accessibility in metabolomics with MetaboApps. [Kidney Diseases] 信函 | Nature methods | 2026-07-24 | IF 36.1 AIMetaboApps平台通过降低代谢组学数据分析的技术门槛，使临床研究者能够更便捷地利用代谢组学数据支持疾病诊断和预后评估。 18. Nanoparticle-enriched mass spectrometry proteomics in British South Asians identifies links between genetic variants, plasma protein levels and disease risk. [Graves Disease] Nature genetics | 2026-07-24 | IF 31.7 AI该研究首次在南亚裔人群中系统绘制了血浆蛋白的遗传调控图谱，发现多种蛋白质与甲状腺疾病等存在关联，为精准医学在该人群中的临床应用提供了新靶点。摘要Understanding genetic variation associated with differences in plasma protein levels can elucidate human disease mechanisms. Here we demonstrate how untargeted nanoparticle-enriched mass spectrometry (MS)-based plasma proteomics delivers quantitatively and qualitatively different insights compared to two affinity-based assays in a sample of ~1,400 British South Asian individuals. We identify >1,20...查看完整摘要 19. Fibrosis regression in chronic liver disease: the pathologist's view. [Liver Diseases] 综述 | Journal of hepatology | 2026-07-24 | IF 26.8 AI纤维化消退在多种慢性肝病中可实现，但现有分期系统难以准确捕捉这一动态过程，临床需更精准的评估工具指导治疗决策。摘要Numerous observations have indicated that significant amounts of liver fibrosis can either completely disappear or be substantially remodelled following removal of the initiating agent or with therapeutic intervention. Reversal of established cirrhosis has also been documented. Studies of fibrosis reversal utilize semiquantitative staging which was developed for progressive disease and which is li...查看完整摘要 20. Antiviral GHP-88310 blocks contact-mediated and airborne transmission in a ferret model of measles-like disease. [Measles] Nature microbiology | 2026-07-24 | IF 20.5 AIGHP-88310有望成为麻疹接触传播预防用药，对感染源治疗可缩短传染期约5天，具有重要的公共卫生防控意义。摘要The 2025/2026 measles resurgence in North America highlighted that antivirals may be valuable in protecting child health because of mounting vaccination hesitancy. The drug candidate GHP-88310 is an orally efficacious broad-spectrum orthoparamyxovirus polymerase inhibitor, but its effect on viral transmission is unclear. Here we used canine distemper virus, which causes measles-like disease in fer...查看完整摘要在小程序获取完整功能收藏文章、管理订阅、查看本期完整摘要与个性化内容，请前往小程序「医研日新」。前往小程序查看更多内容免责声明：仅供学术交流参考，不构成任何医学建议或诊疗指导

疫苗临床研究临床结果基因疗法

2026-07-21

·安徽省第二人民医院药学部

尼妥珠单抗联合紫杉醇二线治疗EGFR高表达复发转移胃腺癌或食管胃结合部腺癌招募

方案编号：BPL-Nim-GC-3001 胃癌患者招募 01/项目背景由百泰生物药业有限公司申办的“尼妥珠单抗联合紫杉醇二线治疗 EGFR 高表达复发转移胃腺癌或食管胃结合部腺癌的随机、双盲、安慰剂对照 III 期”临床研究正在约 55 家中心开展。本研究已获得国家药品监督管理局和医院伦理委员会的批准，计划在全国招募约 334例 EGFR 高表达复发转移胃腺癌或食管胃结合部腺癌患者，参与研究的患者将有 50%的机会免费使用尼妥珠单抗联合紫杉醇治疗，50%的机会免费使用紫杉醇治疗。 ZHAOMU 02/ 参加本研究的主要条件： 1）年龄≥18 周岁且≤75 周岁的男性或女性； 2) 经病理组织学或细胞学确诊的胃腺癌或食管胃结合部腺癌； 3) 复发转移性疾病，既往接受一线标准化疗方案治疗，或接受过靶向治疗，或接受过免疫治疗，且经研究者确认或病史记录具有明确的疾病进展者； 4) EGFR 阳性； ZHAOMU 03/ 联系列表：城市：合肥医院名称：安徽省第二人民医院地址：安徽省合肥市北二环砀山路 1868 号主要研究者：江浩联系人：王明照联系方式：18324711462 声明如果您符合以上条件，您就可能有机会参加该研究，最终是否入选本研究将由研究医生根据研究要求决定。 • END • 省二院GCP机构办宣

2026-07-20

·ioncology

ESMO 2026丨瞭望前瞻，50余项中国妇科肿瘤研究亮相ESMO，一文速览

编者按 2026年欧洲肿瘤内科学会（ESMO）年会于10月23日至27日在西班牙马德里盛大举办。作为全球肿瘤领域极具影响力的顶级学术盛会，年会汇聚了全球顶尖肿瘤临床专家、科研学者及医药行业从业者，集中展示肿瘤领域前沿基础研究与临床转化成果，引领全球肿瘤诊疗技术发展方向。本次大会妇科肿瘤赛道硕果颇丰，多位中国专家携重磅研究成果亮相，涵盖宫颈癌、卵巢癌、子宫内膜癌等常见妇科恶性肿瘤的靶向治疗、免疫治疗、联合放化疗、真实世界研究及多组学机制探索等多个热门方向，充分展现了中国妇科肿瘤领域的科研实力与临床创新水平。本文系统整理本次ESMO年会收录的中国专家口头报告、壁报研究成果，以期为行业学术交流与临床研究参考提供翔实资料。 ✦ 快速口头报告摘要号：1240RO 英文标题：Iparomlimab and tuvonralimab (QL1706) plus chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (R/M CC): Results from a double-blind, randomized, placebo-controlled phase 3 trial中文标题：艾帕洛利托沃瑞利单抗（QL1706）联合化疗±贝伐珠单抗一线治疗持续性、复发性或转移性宫颈癌：一项双盲、随机、安慰剂对照Ⅲ期临床试验结果讲者：刘继红教授中山大学肿瘤防治中心摘要号：1243RO 英文标题：JSKN033, a first-in-class subcutaneous (SC)-injected fixed-dose combination (FDC) of biparatopic anti-HER2 ADC and PD-L1 inhibitor, in pre-treated cervical cancer中文标题：全球首创皮下注射双表位抗HER2 ADC联合PD-L1抑制剂固定复方制剂JSKN033用于经治宫颈癌的临床研究讲者：吴小华教授复旦大学附属肿瘤医院妇瘤科摘要号：1244RO 英文标题：SHR-A2102, a novel nectin-4-targeted antibody-drug conjugate, in patients with recurrent or metastatic cervical cancer: results from a phase 2 study中文标题：新型Nectin-4靶向抗体药物偶联物SHR-A2102治疗复发/转移性宫颈癌Ⅱ期临床研究结果讲者：刘继红教授中山大学肿瘤防治中心 ✦ 壁报+电子壁报摘要号：1348eP 英文标题：Association of location of BRCA1/BRCA2 mutations and benefit from PARP inhibitor maintenance in ovarian cancer: a systemic review中文标题：卵巢癌BRCA1/BRCA2突变位点与PARP抑制剂维持治疗获益相关性的系统综述讲者：Ming Wang (Beijing, China) 摘要号：1359eP 英文标题：Role of BTLA in Ovarian Cancer and Its Clinical Prognostic Significance Based on Multi-Omics Analysis.中文标题：基于多组学分析BTLA在卵巢癌中的作用及其临床预后价值讲者：Yiliminuer Abulajiang (Beijing, China) 摘要号：1362eP 英文标题：Multi-omics provide insights into the effect of neoadjuvant chemotherapy on the tumor microenvironment in cervical cancer中文标题：多组学解析新辅助化疗对宫颈癌肿瘤微环境的调控作用讲者：Silu Meng (Wuhan, China) 摘要号：1365eP 英文标题：Updated Efficacy and Safety Data of First-Line Anlotinib + Carboplatin/Paclitaxel Induction Followed by Anlotinib Maintenance in Advanced Ovarian Cancer: Phase II Multicenter Trial (ALTER-GO-010)中文标题：安罗替尼联合卡铂/紫杉醇诱导后安罗替尼维持一线治疗晚期卵巢癌多中心Ⅱ期研究（ALTER-GO-010）更新疗效与安全性数据讲者：Wenjun Cheng (Nanjing, China) 摘要号：1367eP 英文标题：CD8+/FOXP3+ Tumor-Infiltrating Lymphocytes and Systemic Immune-Inflammation Index revealed as a Predictor to Neoadjuvant Cadonilimab Plus Chemotherapy in Advanced Ovarian Cancer from the Phase II CANECT Trial中文标题：Ⅱ期CANECT研究证实CD8+/FOXP3+肿瘤浸润淋巴细胞与全身免疫炎症指数可预测卡度尼利单抗联合化疗新辅助治疗晚期卵巢癌疗效讲者：Jie Tang (Changsha, China) 摘要号：1368eP 英文标题：Clinical Practice Patterns of HER2 Testing and Treatment in Endometrial Cancer in China: A Cross-Sectional Survey中文标题：中国子宫内膜癌HER2检测与治疗临床实践现状横断面调查讲者：Jihong Liu (Guangzhou, China) 摘要号：1371eP 英文标题：Hyperthermic Intraperitoneal Treatment to Enhance the Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Ovarian Cancer: Stage 1 Results of a Phase II Trial (HIPET-IO) (NCT07068178)中文标题：腹腔温热治疗提升晚期卵巢癌免疫检查点抑制剂疗效：Ⅱ期HIPET-IO研究（NCT07068178）I阶段结果讲者：Hui Li (Guangzhou, China) 摘要号：1379eP 英文标题：Safety, Immunogenicity, and Efficacy of RG002, an mRNA-LNP-Based Therapeutic Targeting HPV 16/18 E2/E6/E7, in Patients with CIN2/3: Results from a Phase I and Expanded Clinical Study中文标题：靶向HPV16/18 E2/E6/E7的 mRNA-LNP 治疗疫苗RG002用于CIN2/3患者的安全性、免疫原性及疗效I期及扩展临床研究结果讲者：Shan Cen (Beijing, China) 摘要号：1382eP 英文标题：Study on the Comparison between Fangzhi Decoction and Kangfuxin in Preventing Gastrointestinal Toxicity Induced by Concurrent Chemoradiotherapy for Cervical Cancer中文标题：防芷汤与康复新液预防宫颈癌同步放化疗所致胃肠道毒性对比研究讲者：Shengfa Su (Guiyang, China) 摘要号：1386eP 英文标题：Exploratory study of TP53 mutations in circulating tumor DNA as prognostic and longitudinal monitoring biomarkers for relapsed ovarian carcinoma patients中文标题：循环肿瘤DNA TP53突变作为复发性卵巢癌预后及动态监测生物标志物探索研究讲者：Zheng Feng (Shanghai, China) 摘要号：1388eP 英文标题：Rapid Histopathological Regression of CIN2 with APL-1702 Photodynamic Therapy: Preliminary Findings from a Multicenter Study中文标题：APL-1702光动力治疗实现CIN2快速组织病理学缓解：一项多中心研究初步结果讲者：Yu Zhang (Changsha, China) 摘要号：1394eP 英文标题：Intimate Partner Violence-Related Stress Accelerates Cervical Cancer Development via a Brain–Cholinergic Nerve–Tumor Axis中文标题：亲密伴侣暴力相关应激通过脑-胆碱能神经-肿瘤轴促进宫颈癌进展讲者：Jingrui Jiang (Wuhan, China) 摘要号：1395eP 英文标题：Association of Silva Pattern C with Lymph Node Metastasis Count and Prognosis in Cervical Adenocarcinoma After Radical Hysterectomy : Construction of a Nomogram Prediction Model.中文标题：宫颈腺癌根治术后Silva C型与淋巴结转移数目及预后相关性：列线图预测模型构建讲者：Jiehui Li (Guiyang, China) 摘要号：1396eP 英文标题：Clinical landscape of oncolytic virotherapy in gynecologic malignancies中文标题：溶瘤病毒疗法在妇科恶性肿瘤中的临床应用全景讲者：Kaiyu Fu (Chengdu, China) 摘要号：1403eP 英文标题：RBP4 orchestrates metabolic reprogramming of ovarian cancer and the omentum microenvironment for cancer dissemination中文标题：RBP4调控卵巢癌及大网膜微环境代谢重编程促进肿瘤播散讲者：Weiao Qu (Tianjin, China) 摘要号：1405eP 英文标题：Single-cell RNA sequencing reveals the important role of intercommunication between epithelial cells and cancer-associated fibroblasts in the peritoneal metastasis of high-grade serous ovarian cancer中文标题：单细胞RNA测序揭示上皮细胞与癌相关成纤维细胞互作在高级别浆液性卵巢癌腹膜转移中的关键作用讲者：Xiaoting Zhao (Beijing, China) 摘要号：1406eP 英文标题：Therapy-selected primitive hematopoietic clones in PARP inhibitor–associated t-MN: longitudinal single-cell insights from ovarian cancer中文标题：PARP抑制剂相关治疗相关髓系肿瘤中经药物筛选的原始造血克隆：卵巢癌患者纵向单细胞研究讲者：Yuanqiong Duan (Chengdu, China) 摘要号：1407eP 英文标题：HPV18 is a poor prognostic factor in patients with small cell neuroendocrine cervical cancer.中文标题：HPV18是宫颈小细胞神经内分泌癌不良预后因素讲者：Chyong-Huey Lai (Taoyuan City, Taiwan) 摘要号：1412eP 英文标题：Anxiety-driven sympathetic nerve–CAF–NGF axis promotes ovarian cancer progression and immune evasion中文标题：焦虑介导交感神经-癌相关成纤维细胞-NGF轴促进卵巢癌进展与免疫逃逸讲者：Yueming Zhang (Suzhou, China) 摘要号：1416eP 英文标题：Clinical Characteristics Analysis of a Single-Cell and Spatial Transcriptomics Cohort Treated with Zimberelimab Combined with Chemoradiotherapy for Intermediate- and Advanced-Stage Cervical Cancer中文标题：基于单细胞及空间转录组队列分析Zimberelimab联合放化疗治疗中晚期宫颈癌的临床特征讲者：Yunyan Zhang (Harbin, China) 摘要号：1420eP 英文标题：Epidemiology and Treatment Options for Cervical Cancer Patients Aged ≤25 Years based on SEER database and Real world research中文标题：基于SEER数据库与真实世界研究的25岁及以下宫颈癌患者流行病学特征及治疗方案分析讲者：Chen Ji (Beijing, China) 摘要号：1425eP 英文标题：Real-world outcomes of FRα targeting treatment with MIRV in Chinese PROC patients中文标题：MIRV靶向叶酸受体α治疗中国铂耐药卵巢癌患者真实世界疗效讲者：Jing Li (Shanghai, China) 摘要号：1426eP 英文标题：Correlation Between Recurrence Patterns and Clinical Risk Factors Following Prophylactic Irradiation of the the Inguinal Lymphatic Drainage Area in Stage IIIA Cervical Cancer中文标题：IIIA期宫颈癌腹股沟淋巴引流区预防性放疗后复发模式与临床危险因素相关性讲者：Fenghu Li (Guiyang, China) 摘要号：1427eP 英文标题：Clinical Characteristics and Treatment Strategy Analysis of 21 Cervical Cancer Patients Undergoing Hysterectomy After Radical Radiotherapy中文标题：21例根治性放疗后接受子宫切除术宫颈癌患者临床特征与治疗策略分析讲者：Zhuoying Du (Beijing, China) 摘要号：1428eP 英文标题：Neoadjuvant Iparomlimab and Tuvonralimab (PD-1/CTLA-4 Bifunctional Antibody) Plus Chemotherapy Enables Radical Surgery in Locally Advanced Cervical Cancer中文标题：PD-1/CTLA-4双特异性抗体艾帕洛利托沃瑞利单抗新辅助化疗可实现局部晚期宫颈癌根治性手术讲者：Wei Sheng (Jinan, China) 摘要号：1430eP 英文标题：Reduced-Dose Dexamethasone (Dex) Plus Netupitant/Palonosetron (NEPA) for Prevention of Nausea and Vomiting in Cervical Cancer Patients Undergoing Concurrent Chemoradiotherapy（CCRT）: An Interim Analysis中文标题：减量地塞米松联合奈妥匹坦/帕洛诺司琼预防宫颈癌同步放化疗恶心呕吐中期分析讲者：Re Yang (Guiyang, China) 摘要号：1440eP 英文标题：MEOX2 promotes the survival and dissemination of ovarian cancer cells via the activation of UPR under nutrient stress中文标题：营养应激下MEOX2通过激活未折叠蛋白反应促进卵巢癌细胞存活与播散讲者：Rui Zhou (Tianjin, China) 摘要号：1441eTiP 英文标题：Prospective Single-Arm Exploratory Study of Disitamab Vedotin Combination Regimen as Neoadjuvant Therapy for HER2-Expressing Ovarian Cancer中文标题：维迪西妥单抗联合方案用于HER2表达卵巢癌新辅助治疗前瞻性单臂探索研究讲者：Jing X. Tong (Shenyang, China) 摘要号：1253P 英文标题：Biparatopic Anti-HER2 Antibody Drug Conjugate (ADC) JSKN003 in Platinum-Resistant Ovarian Cancer (PROC): updated Overall Survival (OS) Analysis from Two Early-Phase Studies After Median Follow-Up (mFU) of 20.5 Months中文标题：双表位抗HER2 ADC药物JSKN003治疗铂耐药卵巢癌：两项早期研究中位随访20.5个月更新总生存数据讲者：Xiaohua Wu (Shanghai, China) 摘要号：1254P 英文标题：Disitamab Vedotin (RC48)-based Therapy in Heavily Prior Treated Patients with Recurrent Ovarian Cancer: A Real-World Multicenter Study中文标题：基于维迪西妥单抗（RC48）方案治疗多线经治复发性卵巢癌多中心真实世界研究讲者：Lei Yuan (Shanghai, China) 摘要号：1255P 英文标题：Elfetabart drozuntecan (Elfe-D; DB-1311/BNT324 [B7H3 ADC]) in patients with platinum-resistant ovarian cancer (PROC): Efficacy and safety data from a Phase 2 dose optimization cohort中文标题：B7H3 ADC药物 Elfetabart drozuntecan（DB-1311/BNT324）治疗铂耐药卵巢癌Ⅱ期剂量优化队列疗效与安全性数据讲者：Jianqing Zhu (Hangzhou, China) 摘要号：1259P 英文标题：Sacituzumab Tirumotecan (Sac-TMT) + Pembrolizumab (Pembro) in Post-Platinum Advanced Mismatch Repair Proficient (pMMR) Endometrial Cancer (EC): Results From a Phase 2 Study (2870-002/SKB264-II-06)中文标题：芦康沙妥珠单抗联合帕博利珠单抗治疗铂耐药晚期错配修复完整子宫内膜癌Ⅱ期研究结果（2870-002/SKB264-II-06）讲者：Xiaohua Wu (Shanghai, China) 摘要号：1260P 英文标题：Updated Progression-Free Survival (PFS) Results from the FLAMES Study: First-Line Maintenance Senaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer (aOC)中文标题：FLAMES研究更新无进展生存数据：塞那帕利一线维持治疗初诊晚期卵巢癌讲者：Xiaohua Wu (Shanghai, China) 摘要号：1265P 英文标题：3-year survival outcomes of image-guided radiotherapy combined with nimotuzumab for elderly patients with locally advanced cervical squamous cell carcinoma: a multi-center phase 2 trial中文标题：图像引导放疗联合尼妥珠单抗治疗老年局部晚期宫颈鳞癌3年生存结局多中心Ⅱ期研究讲者：Ang Qu (Beijing, China) 摘要号：1271P 英文标题：Efficacy and Safety of MSLN-Specific Autologous CAR-T Cell Therapy in Patients with Recurrent Ovarian Cancer: An Investigator-Initiated Single-Arm Clinical Trial中文标题：间皮素靶向自体CAR-T细胞治疗复发性卵巢癌疗效与安全性：一项研究者发起单臂临床试验讲者：Guohui Qin (Zhengzhou, China) 摘要号：1276P 英文标题：Iparomlimab and tuvonralimab (QL1706) plus chemotherapy and definitive radiotherapy as first-line treatment for oligometastatic cervical cancer: a single-arm, phase II study中文标题：艾帕洛利托沃瑞利单抗（QL1706）化疗同步根治性放疗一线治疗寡转移宫颈癌单臂Ⅱ期研究讲者：Jing Liu (Jinan, China) 摘要号：1277P 英文标题：Iparomlimab and tuvonralimab (QL1706) plus chemotherapy with or without bevacizumab induced concurrent chemoradiotherapy for high-risk locally advanced cervical cancer: A Prospective, Single-Arm Phase II Clinical Trial中文标题：艾帕洛利托沃瑞利单抗（QL1706）±贝伐珠单抗化疗诱导同步放化疗治疗高危局部晚期宫颈癌前瞻性单臂Ⅱ期临床研究讲者：Xiao'juan Lv (Hangzhou, China) 摘要号：1280P 英文标题：Long Term Follow-up Results from a Phase I/II Study of Nilvanstomig (ZG005), a Bispecific Antibody Targeting PD-1 and TIGIT, as Monotherapy in Patients with Advanced Cervical Cancer中文标题：PD-1/TIGIT双特异性抗体 Nilvanstomig（ZG005）单药治疗晚期宫颈癌I/Ⅱ期长期随访结果讲者：Shuxia Cheng (Zhengzhou, China) 摘要号：1282P 英文标题：Phase I/II Study of Nilvanstomig (ZG005) Combined with Chemotherapy with or without Bevacizumab as First-Line Treatment for Advanced Cervical Cancer: Updated Results of Efficacy and Safety中文标题：PD-1/TIGIT双特异性抗体 Nilvanstomig（ZG005）联合化疗±贝伐珠单抗一线治疗晚期宫颈癌 I/Ⅱ期更新疗效与安全性数据讲者：Hanmei Lou (Hangzhou, China) 摘要号：1283P 英文标题：Phase II Study of Fruquintinib Plus Utidelone in Platinum-Resistant Recurrent Ovarian Cancer (FRUTD Trial)中文标题：呋喹替尼联合优替德隆治疗铂耐药复发性卵巢癌Ⅱ期FRUTD临床研究讲者：Zheng Feng (Shanghai, China) 摘要号：1289P 英文标题：Subtype-Specific Outcomes and Risk-Adapted Treatment Patterns in Endometrial Stromal Sarcoma: A 214-Patient Retrospective Cohort中文标题：子宫内膜间质肉瘤各亚型生存结局及风险分层治疗模式：214例患者回顾性队列研究讲者：Lingcong Yang (Fuzhou, China) 摘要号：1297P 英文标题：Preliminary outcomes of a phase II study of the highly potent PI3K/mTOR dual inhibitor WX390 monotherapy in patients with platinum-resistant ovarian clear cell carcinoma harboring PIK3CA mutations中文标题：高选择性PI3K/mTOR双靶点抑制剂WX390单药治疗伴PIK3CA突变铂耐药卵巢透明细胞癌Ⅱ期初步结果讲者：Jiajia Li (Shanghai, China) 摘要号：1301P 英文标题：A real-world study of patients with gastric-type adenocarcinoma of the cervix中文标题：宫颈胃型腺癌患者真实世界临床研究讲者：Mengting Che (Chengdu, China) 摘要号：1303P 英文标题：Efficacy of Iparomlimab and Tuvonralimab (QL1706) in Cervical Cancer: A Multicenter, Prospective, Real-World Study中文标题：艾帕洛利托沃瑞利单抗（QL1706）治疗宫颈癌多中心前瞻性真实世界疗效研究讲者：Yan Lu (Nantong, China) 摘要号：1315P 英文标题：Redefining risk in cervical cancer: a novel histology-site subtype framework uncovers high- Risk adenocarcinoma through risk reversal中文标题：宫颈癌风险分层再定义：全新组织 - 解剖分型体系通过风险反转识别高危腺癌亚型讲者：Xiaolian Peng (Dongguan, China) 摘要号：1326P 英文标题：Induction Weekly Chemoimmunotherapy with Enlonstobart as a Priming Approach to De-escalated Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer中文标题：恩朗苏拜单抗周疗化疗免疫诱导方案用于局部晚期宫颈癌降阶梯同步放化疗预处理讲者：Ai Huang (Wuhan, China) 摘要号：1327P 英文标题：Longitudinal Changes of Systemic Tumoe Immune Envoriment (STIE) in Cervical Cancer Patients Receiving Radiotherapy中文标题：接受放疗的宫颈癌患者全身肿瘤免疫微环境纵向动态变化规律讲者：Caining Zhao (Shenzhen, China) （来源：《肿瘤瞭望》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

100 项与尼妥珠单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	尼妥珠单抗	L01XC	DB06192

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
胰腺癌	中国	百泰生物药业有限公司	2023-06-07
头颈部鳞状细胞癌	印尼	Innogene Kalbiotech Pte Ltd.	2022-10-19
鼻咽癌	中国	Biotech Pharmaceuticals Pty Ltd	2008-01-07
胶质瘤	乌克兰	Oncoscience AG	2007-10-10
头颈部肿瘤	印度	Biocon Biopharmaceuticals Pvt Ltd.	2006-09-11

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
胃食管交界处腺癌	临床3期	中国	百泰生物药业有限公司	2024-08-01
胃食管交界处癌	临床3期	中国	百泰生物药业有限公司	2024-08-01
胃腺癌	临床3期	中国	百泰生物药业有限公司	2024-08-01
转移性结直肠癌	临床3期	-	百泰生物药业有限公司	2024-04-01
晚期头颈部鳞状细胞癌	临床3期	中国	百泰生物药业有限公司	2021-11-01
弥漫内生性脑桥神经胶质瘤	临床3期	中国	百泰生物药业有限公司	2021-04-03
宫颈鳞状细胞癌	临床3期	中国	百泰生物药业有限公司	2016-05-10
食管鳞状细胞癌	临床3期	中国	百泰生物药业有限公司	2015-11-13
转移性食管鳞状细胞癌	临床3期	中国	百泰生物药业有限公司	2015-11-01
宫颈癌	临床3期	阿尔及利亚	-	2015-10-28

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ChiCTR2200063875 (ASCO2026)	临床2期	复发性食管鳞状细胞癌	42	Nimotuzumab + CCRT	蓋蓋製齋齋醖鹹窪膚艱(遞廠鹹鬱糧觸夢繭淵壓) = 廠淵鏇選遞衊製構襯艱壓鹽構壓窪蓋簾膚膚簾 (壓餘繭選鑰廠壓艱憲願 ) 更多	积极	2026-05-29
NCT06879691 (ASCO2026)	临床3期	头颈部肿瘤	194	nimotuzumab + analgesics + CCRT	製遞簾繭艱鹹遞積獵製(網餘構獵遞顧壓餘鏇積) = 鬱觸艱淵壓網範醖繭獵簾窪遞獵齋襯糧願網顧 (淵積壓繭築鑰鹹鹽鹹蓋 ) 更多	积极	2026-05-29
				analgesics + CCRT	製遞簾繭艱鹹遞積獵製(網餘構獵遞顧壓餘鏇積) = 網築製遞艱齋鬱觸網廠簾窪遞獵齋襯糧願網顧 (淵積壓繭築鑰鹹鹽鹹蓋 ) 更多
ASCO2026	N/A	转移性食管鳞状细胞癌一线 EGFR gene amplification	497	Nimotuzumab + Paclitaxel + Cisplatin	範糧簾蓋蓋鏇積膚鬱願(廠齋窪膚網鏇範鬱鏇鑰) = 繭遞壓窪顧窪鏇鏇淵淵遞憲醖簾鹽網獵齋壓壓 (觸鹽醖衊廠獵遞積壓衊 ) 更多	积极	2026-05-29
				Placebo + Paclitaxel + Cisplatin	範糧簾蓋蓋鏇積膚鬱願(廠齋窪膚網鏇範鬱鏇鑰) = 壓選鑰範繭鬱衊廠鬱鹹遞憲醖簾鹽網獵齋壓壓 (觸鹽醖衊廠獵遞積壓衊 ) 更多
ASCO2026	N/A	局部晚期头颈部鳞状细胞癌	75	Concurrent chemoradiotherapy (CCRT) (Intermediate high-risk (e.g., pT3-4, N2-3))	繭糧鑰齋壓網窪窪鏇淵(鹹夢艱積繭膚憲衊繭廠) = 蓋鹹鹽製齋製衊壓齋壓選觸鹹衊繭鑰衊糧築糧 (繭鬱醖廠憲蓋壓鏇觸鏇 ) 更多	积极	2026-05-29
				nimotuzumab plus CCRT (Extranodal extension/positive margins)	繭糧鑰齋壓網窪窪鏇淵(鹹夢艱積繭膚憲衊繭廠) = 糧廠廠範構膚築網鏇獵選觸鹹衊繭鑰衊糧築糧 (繭鬱醖廠憲蓋壓鏇觸鏇 ) 更多
NCT06048913 (ASCO2026)	临床2期	食管鳞状细胞癌	56	Nimotuzumab plus S-1 and concurrent radiotherapy	壓遞衊鏇網選顧蓋獵築(願憲願鏇醖鏇簾蓋選選) = 襯鑰壓願選觸選壓鏇願繭顧鏇齋夢窪醖獵製齋 (顧壓築餘製醖憲廠構衊, 55.5 ~ 80.1) 更多	积极	2026-05-29
ASCO2026	N/A	胰腺癌新辅助 EGFR expression	100	AG regimen alone	築製顧顧構夢襯襯壓鏇(鑰簾製夢糧醖觸鏇觸鹹) = 鏇艱淵窪膚艱膚衊獵選範鏇願製壓製鬱構膚繭 (繭遞簾鏇遞積觸廠繭選 ) 更多	积极	2026-05-29
				AG regimen + nimotuzumab	築製顧顧構夢襯襯壓鏇(鑰簾製夢糧醖觸鏇觸鹹) = 衊膚糧齋餘壓壓顧淵艱範鏇願製壓製鬱構膚繭 (繭遞簾鏇遞積觸廠繭選 ) 更多
AACR2026	N/A	肝转移 CXCR4 \| LITAF	23	Nimotuzumab plus AG	簾襯鑰網鏇蓋積窪糧淵(製鹽襯鑰壓憲淵膚遞襯) = 鏇襯範壓衊構淵齋齋鹽選窪廠觸積網獵窪艱餘 (憲築廠簾衊製網鑰範壓 ) 更多	积极	2026-04-19
NCT04223024 (Pubmed \| Nat Commun)	临床2期	晚期鼻咽癌	246	Nimotuzumab plus Concurrent Chemoradiotherapy	積廠簾遞蓋鏇遞製醖齋(選壓膚壓廠膚壓積願簾) = 淵觸憲膚鏇觸淵獵餘獵獵憲壓淵顧獵衊鹹願遞 (顧衊醖築選壓積衊鹽鏇, 74.3 ~ 86.1)	不佳	2026-03-31
				Concurrent Chemoradiotherapy	積廠簾遞蓋鏇遞製醖齋(選壓膚壓廠膚壓積願簾) = 鬱鑰淵夢顧選鹽餘艱觸獵憲壓淵顧獵衊鹹願遞 (顧衊醖築選壓積衊鹽鏇, 74.2 ~ 85.7)
ESMO_ASIA2025	临床3期	晚期鼻咽癌	352	nimotuzumab during induction chemotherapy	選窪齋築廠膚蓋窪願鏇(顧觸鹹製廠窪範襯鏇膚) = 齋齋獵餘網鬱製觸選鏇選積餘築顧蓋餘齋鏇獵 (襯醖餘願膚餘範壓獵餘 ) 更多	积极	2025-12-06
				nimotuzumab during CCRT	選窪齋築廠膚蓋窪願鏇(顧觸鹹製廠窪範襯鏇膚) = 鹹壓積膚艱艱簾遞鏇積選積餘築顧蓋餘齋鏇獵 (襯醖餘願膚餘範壓獵餘 ) 更多
NCT06414577 (ESMO_ASIA2025)	临床2期	难治性鼻咽癌	36	Liposomal irinotecan 70 mg/m2+nimotuzumab 400 mg	膚鹹鹽襯膚蓋築鹹膚齋(繭鏇襯遞繭蓋鹽鬱願鏇) = 鏇遞糧製願窪蓋襯糧築繭淵齋廠廠齋憲遞襯餘 (簾廠觸願網範鏇網憲襯 ) 更多	积极	2025-12-06